VA-CEA
The 2014 CES was named this week by Trade Show Executive’s Gold 100 Awards & Summit as the Largest Annual Show (for the eighth consecutive year), Fastest Growing Show and Show with Strongest Global Participation. Trade Show Executive’s Gold 100 Awards & Summit honors the 100 largest trade shows that have set the gold standard for the trade show industry.
CES is the world’s gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for more than 45 years—the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the consumer technology industry.
“We work hard to create an event experience that keeps exhibitors, attendees and press coming back year after year and it means a lot to be recognized by TSE, a leader in the events industry,” said Karen Chupka, senior vice president, CES and corporate business strategy, Consumer Electronics Association (CEA)®, owner and producer of CES. “These awards recognize our innovative thinking and strategic efforts aimed at making CES the world’s must-attend technology event.”
In total, 160,498 industry influencers attended the 2014 CES, including 6,575 media and 40,828 international attendees from 144 countries. The highest number of international attendees came from Canada, South Korea, China, Japan, Mexico, the United Kingdom, Taiwan and France; each country represented by more than 1,000 attendees at the 2014 CES.
CEA works closely with the Las Vegas Convention Visitors Authority (LVCVA) to ensure smooth travel and accommodations for all guests. In 2014 international travel to Las Vegas got a tremendous boost, with the Las Vegas McCarren International Airport’s opening of Terminal 3 and its seven dedicated international gates. CEA promoted the new terminal and the fact that the Customs and Border Protection area could process 2,000 international passengers an hour, made CES even more accessible and attractive to a global audience.
The 2015 CES was even larger than 2014 with 176, 676 industry influencers in attendance. Including 48, 833 international attendees from 153 countries. CES 2016® will take place Wednesday, January 6-Saturday, January 9, 2016, in Las Vegas, Nevada. Registration for CES 2016 is now available. Please visit CESweb.org for more information.
Note to Editors: The official name of the global technology event is “CES ® .” Please do not use “Consumer Electronics Show” or “International CES” to refer to the event.
About CES:
CES is the world’s gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for more than 40 years—the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the industry. And because it is owned and produced by the Consumer Electronics Association (CEA), the technology trade association representing the $285 billion U.S. consumer electronics industry, it attracts the world’s business leaders and pioneering thinkers to a forum where the industry’s most relevant issues are addressed. Check out CES video highlights . Follow CES online at www.CESweb.org and on social .
UPCOMING EVENTS
-
CES Unveiled Paris -
Register
October 21, 2015, Paris, France
-
CEA Innovate! -
Register
November 8-10, 2015, New York, NY
-
CE Hall of Fame Dinner -
Register
November 9, 2015, New York, NY
-
CES Unveiled New York –
Register
November 10, 2015, New York, NY
-
CES Unveiled Las Vegas
January 4, 2016, Las Vegas, NV
-
CES 2016
January 6-9, 2016, Las Vegas, NV
-
CEA Winter Break
March 21-24, 2016, Park City, UT
-
CES Asia 2016
May 11-13, 2016, Shanghai, China
View source version on businesswire.com: http://www.businesswire.com/news/home/20151008006319/en/
Contact:
Consumer Electronics Association
Allison Fried,
703-907-7603
afried@CE.org
www.CE.org
or
Krista
Silano, 703-907-4331
ksilano@CE.org
www.CESweb.org
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom